TScan Therapeutics Q3 2026 net loss narrows 7% to $33.1 million

By Public Technologies
  • TScan Therapeutics’ third-quarter 2026 net loss narrowed 7% year over year to $33.1 million.
  • Revenue fell 76% year over year to $600,000, primarily due to timing of research activities under its Amgen collaboration.
  • Cash and cash equivalents totaled $73 million at September 30, sufficient to fund operations into the fourth quarter of 2027.
  • A strategic reorganization prioritized in vivo-engineered TCR-T therapies for solid tumors, with first patient dosing targeted for the fourth quarter of 2027.
  • Further enrollment in Phase 3 ALLOHA-2 was paused due to insufficient capital to complete the trial; strategic partners are being sought.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456865), on November 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk